Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8⁺ T cells.

ABSTRACT:

Objectives

Bispecific antibodies targeting CD47 and PD-L1 (CD47 × PD-L1 BisAb) demonstrate efficacy against a range of solid cancers. While dual blockade negates anti-CD47-mediated toxicity, the effect of combined innate and adaptive immune activation on protective tumor-resident CD8⁺ T cells has yet to be fully elucidated.

Methods

CD8⁺ T cell populations were tracked upon CD47 × PD-L1 BisAb treatment in an orthotopic model of murine breast cancer where anti-tumor immunity is mediated by CD8⁺ T cells. Immune responses were also compared with anti-PD-L1 monotherapy to assess the advantage of dual checkpoint targeting.

Results

We found that CD47 × PD-L1 BisAb treatment augmented CD8⁺ T cell responses in tumors, which resulted

SUBMITTER: Christo SN 

PROVIDER: S-EPMC11583082 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature